08-13-04





## Express Mail No. EV452773050US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dingivan et al.

Confirmation No.: 3565

Application No.: 10/657,006

Group Art Unit: 1614

Filed: September 5, 2003

Examiner: To Be Assigned

For: METHODS OF PREVENTING OR

Attorney Docket No.: 10271-116-999

TREATING T CELL MALIGNANCIES BY ADMINISTERING CD2

**ANTAGONISTS** 

## PRELIMINARY AMENDMENT UNDER 37 C.F.R. § 1.115

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to Rule 115 of the Rules of Practice and in connection with the above-identified application, please enter the following amendment and consider the following remarks.

No fee is believed to be due for this submission. However, should any fees be required, please charge such fees to Jones Day Deposit Account No. 50-3013.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 7 of this paper.